BioSpace News Archive

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, today announced that Herbert Harris, M.D., Ph.D., Executive Vice President, Translational Medicine of Tonix Pharmaceuticals, delivered an oral presentation on March 23, 2023, at the Rare Disease Innovation and Partnership Summit being held as a hybrid event in Philadelphia, Pa.

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced financial results for the fourth quarter and full year 2022 and provided corporate and clinical development updates.

Mangoceuticals, Inc. (“MangoRx” or the “Company”) (NASDAQ:MGRX), a company focused on developing, marketing and selling a variety of men’s health and wellness products via a secure telemedicine platform, including its uniquely formulated erectile dysfunction (ED) drug branded “Mango,” today announced the closing of its initial public offering of 1,250,000 shares of common stock at a public offering price of $4.00 per share.

Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today provided a corporate update and reported financial results for the fourth quarter ended December 31, 2022.

Aptose Biosciences Inc. announced financial results for the fourth quarter and year ended December 31, 2022, and provided a corporate update.

Helius Medical Technologies, Inc. announced that its Board of Directors declared a dividend of one one-thousandth of a share of newly designated Series B Preferred Stock, par value $0.001 per share, for each outstanding share of Helius Class A common stock held of record on April 3, 2023.

BIOASIS TECHNOLOGIES INC., a multi-asset rare and orphan disease biopharmaceutical company developing clinical stage programs based on epidermal growth factor and a differentiated, proprietary xB3 ™ platform for delivering therapeutics across the blood-brain barrier and the treatment of central nervous system disorders in areas of high unmet medical need provides this update on its business operations.

Graf Acquisition Corp. IV and NKGen Biotech, Inc. announced that they have signed a non-binding letter of intent to pursue a business combination.

Agilent Technologies Inc. announced that the recipient of the 2023 Darlene Solomon Award is Kathryn Wolhuter, Ph.D., a senior postdoctoral researcher studying coronary heart disease at the Victor Chang Cardiac Research Institute in Sydney, Australia.

Chinook Therapeutics, Inc. today announced presentations at the ISN World Congress of Nephrology 2023 from March 30 – April 2, 2023 in Bangkok, Thailand.